Dmitry I. Gukosyan
Dmitry I. Gukosyan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander Alekseevich Pushkov
National Medical Research Center for Children’s Health, Ministry of Health of Russian Federation
1 shared publication - Anastasiya A. Lyalina
National Medical Research Center for Children’s Health
1 shared publication - I. G. Shchukina
Regional Children’s Clinical Hospital No. 2
1 shared publication - I. S. Bakhtin
Children’s Regional Clinical Hospital, Ministry of Health of Krasnodar Region
1 shared publication - I. V. Volkov
St. Valentine Epileptology Center
1 shared publication - K. Yu. Mukhin
Svt. Luka’s Institute of Child Neurology and Epilepsy
1 shared publication
Latest Publications
- Open Access
- 31 January 2025
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 5 (4) , 225-232
Clinical case of a patient with AADC deficiency of L-aromatic amino acid decarboxylase: diagnostic route and therapeutic options
L-aromatic amino acid decarboxylase deficiency (AADC) is a rare autosomal recessive neurometabolic disease characterized by impaired biosynthesis of neurotransmitters and manifested by disorders of movement and autonomic regulation. In the article there is discussed the diagnostic path and treatment options for a 7-year patient with severe AADC deficiency. Combination of severe neurological disorders (muscular hypotension, dystonia, hyperkinesis, oculogyric crises) and autonomic disorders (increased sweating, hypersalivation, thermoregulation disorders, nasal congestion, dyspepsia, etc.) is clearly demonstrated to require the detection of 3-O-methyldopa in dried blood spots to exclude AADC deficiency. Given the emergence of gene therapy, which is available to patients with a confirmed diagnosis of AADC deficiency in Russia within the criteria of the Circle of Kindness Foundation, it is necessary to popularize information about L-aromatic amino acid decarboxylase deficiency in the general medical community, to improve the prognosis and quality of life in AADC patients.
- 31 January 2025
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 5 (4) , 225-232
Open AccessClinical case of a patient with AADC deficiency of L-aromatic amino acid decarboxylase: diagnostic route and therapeutic options
L-aromatic amino acid decarboxylase deficiency (AADC) is a rare autosomal recessive neurometabolic disease characterized by impaired biosynthesis of neurotransmitters and manifested by disorders of movement and autonomic regulation. In the article there is discussed the diagnostic path and treatment options for a 7-year patient with severe AADC deficiency. Combination of severe neurological disorders (muscular hypotension, dystonia, hyperkinesis, oculogyric crises) and autonomic disorders (increased sweating, hypersalivation, thermoregulation disorders, nasal congestion, dyspepsia, etc.) is clearly demonstrated to require the detection of 3-O-methyldopa in dried blood spots to exclude AADC deficiency. Given the emergence of gene therapy, which is available to patients with a confirmed diagnosis of AADC deficiency in Russia within the criteria of the Circle of Kindness Foundation, it is necessary to popularize information about L-aromatic amino acid decarboxylase deficiency in the general medical community, to improve the prognosis and quality of life in AADC patients.
- Open Access
- 15 April 2024
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 19 (2) , 20-32
Experience of using zonisamide in children in routine clinical practice (a multicenter study)
Background. The problem of antiepileptic therapy in children remains highly relevant due to the insufficient efficacy of standard drugs, adverse events, and limitations of clinical guidelines.Aim. To assess the efficacy, tolerability, and continuation of zonisamide (Zonegran) therapy in children with epilepsy.Materials and methods. This retrospective multicenter study was conducted in epileptology centers in various regions of the Russian Federation, including Moscow, Novosibirsk, Krasnodar, Tyumen, Krasnoyarsk, Voronezh, Ryazan). We included 340 patients under the age of 18 (202 boys and 138 girls) with various epileptic syndromes receiving zonisamide (mean age was 10.63 years). Zonisamide was administered to patients with the following epileptic syndromes: age-dependent self-limited focal epilepsy of childhood (n = 49; 14 %) structural focal epilepsy (n = 102; 30 %), focal epilepsy of childhood with structural brain changes and benign epileptiform discharges of childhood visualized at electroencephalography (n = 38; 11.2 %), idiopathic generalized epilepsy (n = 23; 6.7 %), developmental and epileptic encephalopathies (n = 44; 12.9 %) (including developmental and epileptic encephalopathies with spike-and-wave activation during sleep (n = 23; 6.7 %)), Lennox–Gastaut syndrome and infantile epileptic spasms syndrome (n = 32; 9.4 %), genetic epilepsy with generalized and focal seizures (n = 81; 23.8 %). The type of the seizures was distributed as follows: focal motor (n = 205), bilateral tonic-clonic (n = 192), generalized (n = 197), including generalized convulsive (n = 44), tonic (n = 70), atonic (n = 2), myoclonic (n = 26), epileptic spasms (n = 36), absence seizures (n = 19). One patient could have more than one type of seizures. Magnetic resonance imaging demonstrated some changes in 185 patients, whereas 117 patients had no magnetic resonance imaging changes. Thirty-eight patients did not undergo magnetic resonance imaging as they had no indications to it. The most common structural epileptogenic changes were the consequences of perinatal lesions manifesting as cystic-gliotic transformation, atrophy (125 cases in total); less common changes included focal cortical dysplasia, developmental abnormalities (such as polymicrogyria, lissencephaly, holoprosencephaly), mesial temporal sclerosis, and tumors. Zonegran (zonisamide) as an additional therapy was administered at a dose of 3–8 mg/kg/day (mean dose 5 mg/kg/day) to 321 patients.Results. Zonegran (zonisamide) therapy was effective in 257 (75.6 %) of patients; remission was achieved in 174 patients (67.7 %), while reduced seizure frequency (50 % and greater) was registered in 83 patients (32.3 %). A total of 72 patients (21.2 %) reported no adverse events. Twenty participants (5.8 %) had some adverse events; in 4 cases, they were resolved after dosage decrease; in 16 cases, treatment with zonisamide was discontinued.Conclusion. Zonegran (zonisamide) is effective for comprehensive treatment of both focal and generalized epilepsy in children*.
- 15 April 2024
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 19 (2) , 20-32
Open AccessExperience of using zonisamide in children in routine clinical practice (a multicenter study)
Background. The problem of antiepileptic therapy in children remains highly relevant due to the insufficient efficacy of standard drugs, adverse events, and limitations of clinical guidelines.Aim. To assess the efficacy, tolerability, and continuation of zonisamide (Zonegran) therapy in children with epilepsy.Materials and methods. This retrospective multicenter study was conducted in epileptology centers in various regions of the Russian Federation, including Moscow, Novosibirsk, Krasnodar, Tyumen, Krasnoyarsk, Voronezh, Ryazan). We included 340 patients under the age of 18 (202 boys and 138 girls) with various epileptic syndromes receiving zonisamide (mean age was 10.63 years). Zonisamide was administered to patients with the following epileptic syndromes: age-dependent self-limited focal epilepsy of childhood (n = 49; 14 %) structural focal epilepsy (n = 102; 30 %), focal epilepsy of childhood with structural brain changes and benign epileptiform discharges of childhood visualized at electroencephalography (n = 38; 11.2 %), idiopathic generalized epilepsy (n = 23; 6.7 %), developmental and epileptic encephalopathies (n = 44; 12.9 %) (including developmental and epileptic encephalopathies with spike-and-wave activation during sleep (n = 23; 6.7 %)), Lennox–Gastaut syndrome and infantile epileptic spasms syndrome (n = 32; 9.4 %), genetic epilepsy with generalized and focal seizures (n = 81; 23.8 %). The type of the seizures was distributed as follows: focal motor (n = 205), bilateral tonic-clonic (n = 192), generalized (n = 197), including generalized convulsive (n = 44), tonic (n = 70), atonic (n = 2), myoclonic (n = 26), epileptic spasms (n = 36), absence seizures (n = 19). One patient could have more than one type of seizures. Magnetic resonance imaging demonstrated some changes in 185 patients, whereas 117 patients had no magnetic resonance imaging changes. Thirty-eight patients did not undergo magnetic resonance imaging as they had no indications to it. The most common structural epileptogenic changes were the consequences of perinatal lesions manifesting as cystic-gliotic transformation, atrophy (125 cases in total); less common changes included focal cortical dysplasia, developmental abnormalities (such as polymicrogyria, lissencephaly, holoprosencephaly), mesial temporal sclerosis, and tumors. Zonegran (zonisamide) as an additional therapy was administered at a dose of 3–8 mg/kg/day (mean dose 5 mg/kg/day) to 321 patients.Results. Zonegran (zonisamide) therapy was effective in 257 (75.6 %) of patients; remission was achieved in 174 patients (67.7 %), while reduced seizure frequency (50 % and greater) was registered in 83 patients (32.3 %). A total of 72 patients (21.2 %) reported no adverse events. Twenty participants (5.8 %) had some adverse events; in 4 cases, they were resolved after dosage decrease; in 16 cases, treatment with zonisamide was discontinued.Conclusion. Zonegran (zonisamide) is effective for comprehensive treatment of both focal and generalized epilepsy in children*.